Yahoo Finance

Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Clene (CLNN) to $83 from $86 and keeps a Buy rating on the shares. The firm noted they reported results with the key update for that the company held its planned meeting with the FDA on Novemebr 01 to discuss the potential to file a new drug application (NDA) for CNM-Au8 (nanocrystalline gold) for amyotrophic lateral sclerosis (ALS) under an accelerated approval pathway. Canaccord noted the company did not provide any characterization of the outcome of the meeting, which we view as the key near-term stock driver.

Don't Miss our Black Friday Offers:

• Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks

• Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on CLNN:

• Clene Announces Q3 2024 Results and ALS Drug Progress

• Clene reports Q3 EPS ($1.22), consensus ($1.32)

• CLNN Upcoming Earnings Report: What to Expect?

• Clene Unveils Phase 3 Trial Design at NEALS

• Clene price target lowered to $86 from $94 at Canaccord